Onheel Signs Sales Agreement with CMG Pharmaceutical for PF72, Aiming for 10 Billion Won in Single Product Sales

Onheel, a company specializing in pet care and healthcare, announced on April 16, 2026, that it has entered into a strategic agreement with CMG Pharmaceutical for the sales of the next-generation drug delivery medical device, PF72. This collaboration aims to accelerate the market entry of PF72 by combining its advanced technology with CMG Pharmaceutical’s medical network, and to achieve rapid growth in initial sales.

PF72 is a product featuring Tizel Bio’s proprietary drug delivery platform. It remains in liquid form at room temperature but transforms into a gel after being injected into the body. This allows the drug to stay stably at the target site and continue to alleviate pain for up to 72 hours. The product is evaluated as offering superior convenience and sustained effect compared to conventional local injectables or short-acting formulations.

The company stated, “PF72 is a product that combines technical excellence and market potential. Beyond simple distribution, it is expected to become a core growth driver for the company. Through collaboration with CMG Pharmaceutical, we plan to pursue both rapid market penetration and tangible sales generation.”

The industry is paying attention to PF72 as a potential case for the commercialization of drug delivery technology. In particular, there are high expectations for market expansion, as its application is anticipated to broaden in fields such as orthopedics, pain medicine, and obstetrics and gynecology, where pain management is consistently needed after procedures and surgeries.

Under this agreement, Onheel will lead product sales and market expansion, while CMG Pharmaceutical will support initial market entry by leveraging its network focused on CHA Hospital and obstetrics and gynecology clinics. The two companies plan to expand distribution and sales networks nationwide, starting with major medical institutions in the Seoul metropolitan area.

Onheel also expects PF72 to contribute to improved performance. On top of its existing business base, which generates approximately 30 billion won in annual sales, the company has set an additional sales target of 10 billion won for this product alone. Since this single product is structured to drive the overall growth rate, the company is also increasing its strategic focus internally.

The company plans to leverage the distribution and marketing capabilities it has built up in the pet care business to further strengthen a competitive product portfolio in the healthcare sector. Starting with PF72, it will increase the proportion of high value-added products, driving both business structure improvement and enhanced profitability.

This content was produced with the assistance of AI translation services.